Limits...
Tuberculosis treatment outcome monitoring in European Union countries: systematic review.

van Hest R, Ködmön C, Verver S, Erkens CG, Straetemans M, Manissero D, de Vries G - Eur. Respir. J. (2012)

Bottom Line: This review confirmed previous reports of considerable heterogeneity in publications of TOM results across EU/EEA countries.PubMed/MEDLINE and EMBASE indexed studies are not a suitable instrument to measure representative TOM results for the 30 EU/EEA countries.Uniform and complete reporting to the centralised European Surveillance System will produce the most timely and reliable results of TB treatment outcomes in the EU/EEA.

View Article: PubMed Central - PubMed

Affiliation: KNCV Tuberculosis Foundation, The Hague, the Netherlands.

ABSTRACT
Treatment success measured by treatment outcome monitoring (TOM) is a key programmatic output of tuberculosis (TB) control programmes. We performed a systematic literature review on national-level TOM in the 30 European Union (EU)/European Economic Areas (EEA) countries to summarise methods used to collect and report data on TOM. Online reference bibliographic databases PubMed/MEDLINE and EMBASE were searched to identify relevant indexed and non-indexed literature published between January 2000 and August 2010. The search strategy resulted in 615 potentially relevant indexed citations, of which 27 full-text national studies (79 data sets) were included for final analysis. The selected studies were performed in 10 EU/EEA countries and gave a fragmented impression of TOM in the EU/EEA. Publication year, study period, sample size, databases, definitions, variables, patient and outcome categories, and population subgroups varied widely, portraying a very heterogeneous picture. This review confirmed previous reports of considerable heterogeneity in publications of TOM results across EU/EEA countries. PubMed/MEDLINE and EMBASE indexed studies are not a suitable instrument to measure representative TOM results for the 30 EU/EEA countries. Uniform and complete reporting to the centralised European Surveillance System will produce the most timely and reliable results of TB treatment outcomes in the EU/EEA.

Show MeSH

Related in: MedlinePlus

The selection process of articles included in the systematic review. EU: European Union; TOM: treatment outcome monitoring; EEA: European Economic Area.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3585717&req=5

erj-41-03-635-f01: The selection process of articles included in the systematic review. EU: European Union; TOM: treatment outcome monitoring; EEA: European Economic Area.

Mentions: In the systematic literature search, initially 615 potentially relevant indexed citations were retrieved from electronic databases and other sources. After inspection of the titles and abstracts, 530 articles were excluded. Of the 85 articles remaining for full-text screening on eligibility criteria, 12 articles could not be retrieved, despite requests to national focal persons. Of the 73 remaining articles, 19 articles were further excluded after more in-depth scrutiny. Of the 54 remaining full text articles, 27 (79 data sets) were national studies and included for further analysis. One article could contain more than one data (sub)set, i.e. presenting treatment outcomes for more types of TB or for more subgroups of the population. The study selection process is shown in detail in figure 1.


Tuberculosis treatment outcome monitoring in European Union countries: systematic review.

van Hest R, Ködmön C, Verver S, Erkens CG, Straetemans M, Manissero D, de Vries G - Eur. Respir. J. (2012)

The selection process of articles included in the systematic review. EU: European Union; TOM: treatment outcome monitoring; EEA: European Economic Area.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3585717&req=5

erj-41-03-635-f01: The selection process of articles included in the systematic review. EU: European Union; TOM: treatment outcome monitoring; EEA: European Economic Area.
Mentions: In the systematic literature search, initially 615 potentially relevant indexed citations were retrieved from electronic databases and other sources. After inspection of the titles and abstracts, 530 articles were excluded. Of the 85 articles remaining for full-text screening on eligibility criteria, 12 articles could not be retrieved, despite requests to national focal persons. Of the 73 remaining articles, 19 articles were further excluded after more in-depth scrutiny. Of the 54 remaining full text articles, 27 (79 data sets) were national studies and included for further analysis. One article could contain more than one data (sub)set, i.e. presenting treatment outcomes for more types of TB or for more subgroups of the population. The study selection process is shown in detail in figure 1.

Bottom Line: This review confirmed previous reports of considerable heterogeneity in publications of TOM results across EU/EEA countries.PubMed/MEDLINE and EMBASE indexed studies are not a suitable instrument to measure representative TOM results for the 30 EU/EEA countries.Uniform and complete reporting to the centralised European Surveillance System will produce the most timely and reliable results of TB treatment outcomes in the EU/EEA.

View Article: PubMed Central - PubMed

Affiliation: KNCV Tuberculosis Foundation, The Hague, the Netherlands.

ABSTRACT
Treatment success measured by treatment outcome monitoring (TOM) is a key programmatic output of tuberculosis (TB) control programmes. We performed a systematic literature review on national-level TOM in the 30 European Union (EU)/European Economic Areas (EEA) countries to summarise methods used to collect and report data on TOM. Online reference bibliographic databases PubMed/MEDLINE and EMBASE were searched to identify relevant indexed and non-indexed literature published between January 2000 and August 2010. The search strategy resulted in 615 potentially relevant indexed citations, of which 27 full-text national studies (79 data sets) were included for final analysis. The selected studies were performed in 10 EU/EEA countries and gave a fragmented impression of TOM in the EU/EEA. Publication year, study period, sample size, databases, definitions, variables, patient and outcome categories, and population subgroups varied widely, portraying a very heterogeneous picture. This review confirmed previous reports of considerable heterogeneity in publications of TOM results across EU/EEA countries. PubMed/MEDLINE and EMBASE indexed studies are not a suitable instrument to measure representative TOM results for the 30 EU/EEA countries. Uniform and complete reporting to the centralised European Surveillance System will produce the most timely and reliable results of TB treatment outcomes in the EU/EEA.

Show MeSH
Related in: MedlinePlus